1,721,131 research outputs found
Effects of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone deficiency
No full textstudy on the effects of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone deficiency
A four-year dose-response study of recombinant human fgrowth hormone treatment of growth hormone deficient children: effect on growth, bone growth and bone mineralization.
No full textInfluence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children.
No full textEffects of two different regimens of hGH therapy on bone mineral density of patients with GH deficiency.
No full text[Somatotropin function in term and premature newborns during the first month of life]
No full textNeonatal somatotropic function is characterized by a discrepancy between elevated growth hormone (GH) levels and low IGF I levels. This study aimed at explaining this discrepancy, particularly to examining if it could result from low GH bioactivity. Serum concentrations of bioactive GH (bio GH), GH measured by radioimmunoassay (riGH), GH binding protein (GHBP), IGF I and IGF binding proteins (IGFBP) were determined in 27 premature and term newborns during the first month of life. At day 4, riGH and bio GH concentrations were elevated in both premature and term newborns as compared with normal prepubertal children; GHBP and IGF I levels were low, with a positive correlation with gestational age (P < 0.001). There was a positive correlation between GHBP and IGF I levels. IGFBP-1 and IGFBP-2 levels were elevated and negatively correlated with gestational age (P < 0.005). IGFBP-3 levels were within the range of prepubertal children values and positively correlated with gestational age (P < 0.005). During the first month, riGH and bio GH levels decreased in all infants, while IGFI levels increased in premature infants only, and GHBP levels in term infants only. The elevated levels of bio GH during the first days of life appear to be related to the low levels of IGF I due to a reduced number or function of GH receptors. In premature infants the decrease in GH levels observed afterwards appears to be secondary to the increase in IGF I levels. In term infants, in the absence of increase in IGFI levels other(s) factor(s) seem(s) to be involved
Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children.
No full textSubjects and methods: Final height; parentally adjusted final height; the metacarpal index (MI) SIB. the inner and outer diameters: and the total cross-sectional area (CSA). cortical CSA. medullary CSA and bone strength (Bending Breaking Resistance Index (BBRI)) were evaluated at the metacarpal site in two cohorts of GH-deficient children. treated with two different doses of GH. Group 1. (38 patients) was treated with 0.16 mg/kg body weight per week of GH and group 2 (37 patients) with 0.3 mg/kg per week.
Results: At the end of treatment. with group 1 vs group 2. height SDS was -0.84 +/- 1.07 vs -0.46 +/- 0.76. and parentally adjusted height SDS was 0.14 +/- 1.08 vs 0.27 +/- 0.82. Parentally adjusted relative height gain was 1.14 +/- 0.89 vs 2.14 +/- 0.72 SDS (P < 0.000.1). MI SDS was 0.58 +/- 1.31. vs -0.42 +/- 1.54 (P < 0.005). MI SDS gain was 0.07 +/- 1.41 vs -0.35 +/- 1.85. There was no difference between groups in the outer and inner diameter, in the total and cortical CSAs, whereas medullary CSA was higher in group 2 (P < 0.05). BBRI was 10.02 +/- 5.37 vs 11.52 +/- 5.49cm(3), and BBRI gainwas 3.33 +/- 5.06 vs 6.88 +/- 6.65 (P=0.01). P values were assessed using student's t-test.
Conclusion: Higher GH doses result in a greater height gain and improved bone strength
Analysis of growth hormone receptor gene expression in idiopathic tall stature children.
No full textGrowth is a multifactorial process involving genetic, nutritional and other environmental determinants. Because of a major proportion of ultimate stature is dependent upon an intact growth hormone (GH) and insulin-like growth factor I (IGF-I) axis, much attention has been devoted to abnormalities related to these growth factors and their signalling pathways.
At the tissue level, the action of GH result from the interaction of GH with a specific cell surface GH receptor (GHR). Thus, the ability of GH to exert biological effects is intimately linked to the number and function of GHRs in these tissue.
In this study we analyzed the GHR gene expression in peripheral blood mononuclear cells of 31 idiopathic tall children (age: 11,59 ± 0,53 years; height: 2,69 ± 0,13 SDS), and 46 age and sex matched control children of normal stature (age: 10,57 ± 0,42 years; height: -0,24 ± 0,12 SDS) by Real-Time PCR. Normalization and validation of the data will be carried out using GADPH as housekeeping control gene and quantitative Real-time PCR data are expressed as agGHR/5X105 agGAPDH.
We also measured circulating insulin-like growth factor I (IGF-I), by Immulite, in these children in order to investigate if a correlation between levels of this mediator and GHR gene expression level could exist. We found a significantly (p=0,029) higher GHR gene expression value in tall children (976.85 ± 653,4) compared to control children (86,81 ± 19,48); also IGF-I value was significantly (p=0,035) higher in tall children (0,87 ±0,11 SDS) than in control children (0,06 ± 0,19).
In conclusion our preliminary data suggest that an up regulation of GHR gene expression could be responsible for the increased sensibility to GH in tall stature children
- …
